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confirmed a marked presynaptic dopaminergic deficit in the
basal ganglia for both patients, consistent with degenerative
Parkinsonism. Both had asymmetrical parkinsonism (without
dystonia or functional signs) and progressed as expected for
IPD, with typical motor fluctuations in one patient. Patient
B, who was commenced on drug therapy, exhibited a signifi-
cant Levodopa response consistent with IPD. These cases
highlight the potential for IPD to present atypically with
rapid symptom evolution in the presence of significant psy-
chological stress.
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Objective To identify associated (non-)motor profiles of Parkin-
son’s disease (PD) patients with hyperhidrosis.
Methods Cross-sectional analysis of participants enrolled in the
non-motor Longitudinal International Cohort Study (NILS;
UKCRN No: 10084) at the Parkinson’s Centre at King’s Col-
lege Hospital (London, UK). Hyperhidrosis responses (yes/no)
on question 28 of the Non-Motor Symptom Questionnaire
(NMSQ) were used to classify patients with normal sweat
function (n=172) and chronic hyperhidrosis (n=56) (analysis
1; n=228). The grade rating NMS scale (NMSS) question 30
scores were then used for severity grading (analysis 2;
n=352): absent score 0 (n=267), mild 1–4 (n=49), moderate
5–8 (n=17), and severe 9–12 (n=19).
Results Baseline demographics were similar between groups.
Patients with hyperhidrosis exhibited significantly higher
NMSS burden (as graded from total score; p<0.001). Sec-
ondary analyses revealed significantly higher dyskinesia
scores, worse quality of life and sleep, and higher anxiety
levels in hyperhidrosis patients (p<0.001). Tertiary analyses
showed higher scores for dysautonomia (orthostatic hypo-
tension, sialorrhea, constipation, urinary urgency and fre-
quency) as well as fatigue and somnolence, among other
NMS (p<0.001).
Conclusions Chronic hyperhidrosis is associated with a dysau-
tonomia dominant clinical picture combined with fatigue and
somnolence in PD patients. These patients also are likely to
be dyskinetic. This is the first description of motor and non-
motor correlates of hyperhidrosis in PD.
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Background There is strong evidence of mitochondrial dys-
function in both familial and sporadic Parkinson’s disease
(PD). A biomarker reliably identifying mitochondrial
dysfunction would be particularly important for future strati-
fied/personalized medicine trials in Parkinson’s disease. A pre-
vious comparison of serum biomarkers in mitochondrial
disease established that serum growth differentiation factor 15
(GDF-15) outperforms fibroblast growth factor-21 (FGF-21)
and distinguishes patients with mitochondrial diseases from
those without them.
Objective To systematically assess GDF-15, FGF-21 and mito-
chondrial DNA copy number (mtDNA) levels in the serum of
patients with sporadic PD and controls to determine their util-
ity as a suitable mitochondrial biomarker panel for PD.
Methods 120 patients with PD and 102 age-matched controls
were recruited from a single centre. GDF-15, FGF-21 and
mtDNA copy number were quantified using previously estab-
lished assays.
Results FGF-21 concentrations did not significantly differ
between groups. GDF-15 serum levels were significantly
raised in late onset PD compared to controls and early
onset PD. There was no difference in mtDNA between
groups. None of the biomarkers tested showed a significant
association with disease following multivariate logistic
regression analysis.
Conclusion Serum FGF-21, GDF-15 and blood mtDNA could
not accurately differentiate between PD and controls when
assessed as candidate biomarkers.
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Background Non-motor symptoms (NMS) are a significant
cause of morbidity in Parkinson’s, with major impact on qual-
ity of life. There is an urgent need to empower people with
Parkinson’s (PwP) to self-manage NMS, and facilitate timely
intervention. A mobile application (NMS Assist) was devel-
oped, which enables regular assessment of NMS and provides
self-help information in the form of animations.
Aim To evaluate key areas for NMS Assist design
improvement.
Method PwP and carers were recruited from local Parkinson’s
UK groups. NMS Assist user journeys were designed and car-
ried out, filmed with ‘Mr Tappy’, using ‘think aloud’ method-
ology. Satisfaction was evaluated by the System Usability Scale
(SUS).
Results 13 Participants were recruited (PwP, n=9 and carers,
n=4) with varying age, cognition, disease severity and smart-
phone experience. Amendment need was identified in three
key areas: navigation, content and accessibility. There was no
difference in SUS ratings between experienced and never
smartphone users. However, the experienced group had a sig-
nificantly higher error free task completion rate than never
users (p=.01).
Conclusions Refinements to NMS Assist design have been
identified and implemented to improve its usability. The effec-
tiveness of these interventions will be tested in future rounds
of usability testing, leading to in-service evaluation.
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